NCT01605032 · REGISTRY CONDITION SEARCH

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2020-08-20

This phase II trial studies how well busulfan, melphalan, and bortezomib before first-line stem cell transplant works in treating patients with multiple myeloma. Giving chemotherapy before a peripheral blood stem cell transplant may stop the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Rate of Complete Response as Determined by the IMWG Criteria

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Mortality

→

outcome · POSTED

Time-to-progression

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Patients must have histologically or cytologically confirmed multiple myeloma * Measurable disease must be present as defined by protein criteria (quantifiable M-component in serum, urine or serum free light chains) in order to evaluate response as per IMWG; non-secretory patients are eligible provided the patient has \> 20% plasmacytosis OR multiple (\> 3) focal plasmacytomas or focal lesions on magnetic resonance imaging (MRI) * Patients must have received induction chemotherapy for myeloma, but not more than 12 months of prior chemotherapy for this disease, and must be eligible for the first planned autologous transplant * A minimum stem cell dose of 2.0 x 10\^6 cluster of differentiation 34-positive (CD34+) cells/kg has been collected * Life expectancy of greater than 12 months * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Leukocytes \>= 3,000/mcL (unless myeloma related) * Absolute neutrophil count \>= 1,500/mcL (unless myeloma related) * Platelets \>= 50,000/mcL (unless myeloma related) * Total bilirubin =\< 2 x institutional upper limit of normal unless 2nd to Gilbert's disease * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x institutional upper limit of normal * Creatinine =\< 1.5 x institutional upper limit of normal OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Ejection fraction by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) \>= 40% performed within 60 days prior to registration * Patients must have adequate pulmonary function studies: \> 50% of predicted on mechanical aspects (forced expiratory volume in one second \[FEV1\], forced vital capacity \[FVC\]) and diffusion capacity (diffusing capacity of the lung for carbon monoxide \[DLCO\]) \> 50% of predicted, within 60 days of registration; if the patients is unable to complete pulmonary function tests due to multiple myeloma (MM) related pain or condition, exception may be granted if the principal investigator (PI) documents that the patient is a candidate for high dose therapy * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least six months following the stem cell transplantation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Prior treatment history of autologous hematopoietic stem cell transplant (HSCT) or high-dose chemotherapy with stem cell rescue for any medical reason, not limited to myeloma treatment * Patients may not be receiving any other investigational agents * Patients with known brain metastases should be excluded from this clinical trial * History of allergic reactions attributed to compounds of similar chemical or biologic composition to or other agents used in the study, such as busulfan, melphalan, bortezomib, boron, or mannitol * Grade 2 or greater peripheral neuropathy within 14 days prior to enrollment * Unresolved grade \>= 3 non-hematologic toxicity from previous therapy; patients with grade 2 toxicity will be eligible at the discretion of the PI * Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent \< 5 years will not be allowed unless approved by the PI; cancer treated with curative intent \> 5 years will be allowed * Patients must not have significant co-morbid medical condition * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; patients must not have suffered recent (\< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with busulfan * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible * Patients found to have an active hepatitis B infection (hepatitis B surface antigen +) are not eligible unless they meet ONE of the following criteria: * Patient is able to start dual anti-hepatitis (Hep) B therapy prior to enrollment with adefovir and telbivudine * Patient is already on dual anti-hepatitis B therapy * Consultation and co-management with a hepatitis expert regarding hepatitis B treatment is strongly encouraged before and during the trial * Patients, who are positive for hepatitis B core antibody, but negative for the hepatitis B surface antigen, should be started on lamivudine 100 mg daily until at least 3 months post stem cell transplant
healthy Volunteers: false
maximum Age: 72 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4. TRANSPLANT: Patients undergo autologous PBSCT on day 0.
intervention Names
Drug: Busulfan
Drug: Melphalan
Drug: Bortezomib
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
label
Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)
description
Given IV
name
Busulfan
type
DRUG
arm Group Labels
Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)
description
Given IV
name
Melphalan
other Names
Alkeran
type
DRUG
arm Group Labels
Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)
description
Given IV
name
Bortezomib
type
DRUG
arm Group Labels
Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)
description
Undergo autologous PBSCT
name
Autologous Hematopoietic Stem Cell Transplantation
other Names
Autologous Stem Cell Transplantation
type
PROCEDURE
arm Group Labels
Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)
description
Undergo autologous PBSCT
name
Peripheral Blood Stem Cell Transplantation
other Names
PBPC transplantation
Peripheral Blood Progenitor Cell Transplantation
Peripheral Stem Cell Support
Peripheral Stem Cell Transplantation
type
PROCEDURE

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 19
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Number of patients achieved complete response after the treatment regimen
measure
Rate of Complete Response as Determined by the IMWG Criteria
time Frame
Day 100

secondary Outcomes

description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
measure
Overall Response Rate
time Frame
Up to day 100
measure
Mortality
time Frame
Up to day 100
measure
Time-to-progression
time Frame
From start of treatment to disease progression with deaths, up to 2 years
description
The progression free survival was assessed over a period of 2 years
measure
Progression-free Survival
time Frame
2 years
description
The overall survival of patients was measured of a period of 2 years.
measure
Overall Survival
time Frame
2 years

Full study description

brief Summary: This phase II trial studies how well busulfan, melphalan, and bortezomib before first-line stem cell transplant works in treating patients with multiple myeloma. Giving chemotherapy before a peripheral blood stem cell transplant may stop the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
detailed Description: PRIMARY OBJECTIVES: I. To determine the complete response rate as defined by the International Myeloma Working Group (IMWG) criteria for patients with multiple myeloma treated with high dose chemotherapy with pharmacokinetic (PK) directed intravenous (IV) busulfan, bortezomib and melphalan (Bu/BTZ/Mel140) followed by autologous hematopoietic stem cell transplantation (ASCT) as first line therapy. SECONDARY OBJECTIVES: I. To determine the overall response rate of the regimen Bu/BTZ/Mel140. II. To determine the treatment related toxicity and mortality of the regimen, including 100-day mortality rates. III. To determine the duration of response, time to progression, progression-free survival, event-free survival and overall survival for this conditioning regimen. IV. To determine whether there is a gender or race difference in the pharmacokinetic profile of IV busulfan. V. To determine methylation and gene expression signatures of pre-treatment bone marrow plasma cells and explore associations of these signatures with outcome. OUTLINE: CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4. TRANSPLANT: Patients undergo autologous peripheral blood stem cell transplant (PBSCT) on day 0. After completion of study treatment, patients are followed up for up to 5 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-7fcef152eb9b5db6e423
requested nct id
NCT01605032
primary nct id
NCT01605032
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
fe29949e8a99ebe4095b7973b6f18cea6bd5ed7183a0e1ea85f01079f03cb9f1
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-7fcef152eb9b5db6e423
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01605032
occurrences
context exact
NCT01605032
end
11
exact text
NCT01605032
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/797/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
27733dc7959dc12a194d1212f9c5bc00be5224aa13dae41ecc33de8ef4591cac
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice